NCT03381274View on ClinicalTrials.gov

Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 8, 2018

Primary Completion Date

May 24, 2021

Study Completion Date

April 16, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
BIOLOGICAL

Oleclumab

Participants will receive oleclumab in combination with osimertinib or AZD4635 as stated in the arms' description.

DRUG

Osimertinib

Participants will receive osimertinib in combination with oleclumab as stated in the arms' description.

DRUG

AZD4635

Participants will receive AZD4635 in combination with oleclumab as stated in the arms' description.

Trial Locations (13)

10032

Research Site, New York

21224

Research Site, Baltimore

30322

Research Site, Atlanta

40705

Research Site, Taichung

60611

Research Site, Chicago

77030

Research Site, Houston

80045

Research Site, Aurora

92093

Research Site, La Jolla

94143

Research Site, San Francisco

06510

Research Site, New Haven

03080

Research Site, Seoul

05505

Research Site, Seoul

06351

Research Site, Seoul

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY